Ignite Creation Date:
2024-05-06 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 1:53 PM
Study NCT ID:
NCT04691349
Status:
UNKNOWN
Last Update Posted:
2021-01-11
First Post:
2020-12-28
Brief Title:
CAR-T for rr Malignant Tumors in Children
Sponsor:
PersonGen BioTherapeutics Suzhou Co Ltd
Organization:
PersonGen BioTherapeutics Suzhou Co Ltd
Study Overview
Official Title:
Chimeric Antigen Receptor T Cells Therapy for rr Malignant Tumors in Children
Status:
UNKNOWN
Status Verified Date:
2021-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a clinical study of CAR-T treatment of patients with relapsedrefractory malignant tumors in children The purpose is to evaluate the safety and effectiveness of chimeric antigen receptor T cells in the treatment of relapsedrefractory malignant tumors in children
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None